KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Change in Receivables (2016 - 2025)

Quest Diagnostics (DGX) has disclosed Change in Receivables for 17 consecutive years, with -$47.0 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 31.88% to -$47.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $106.0 million through Dec 2025, up 49.3% year-over-year, with the annual reading at $106.0 million for FY2025, 49.3% up from the prior year.
  • Change in Receivables hit -$47.0 million in Q4 2025 for Quest Diagnostics, down from $38.0 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $220.0 million in Q3 2021 to a low of -$138.0 million in Q1 2021.
  • Historically, Change in Receivables has averaged -$6.8 million across 5 years, with a median of -$16.0 million in 2022.
  • Biggest five-year swings in Change in Receivables: plummeted 179.38% in 2021 and later soared 1500.0% in 2025.
  • Year by year, Change in Receivables stood at -$36.0 million in 2021, then plummeted by 133.33% to -$84.0 million in 2022, then rose by 15.48% to -$71.0 million in 2023, then grew by 2.82% to -$69.0 million in 2024, then skyrocketed by 31.88% to -$47.0 million in 2025.
  • Business Quant data shows Change in Receivables for DGX at -$47.0 million in Q4 2025, $38.0 million in Q3 2025, and $14.0 million in Q2 2025.